Vectus Biosystems Ltd (ASX: VBS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Vectus Biosystems Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$8.28 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
53.43 million
Earnings per share
-0.033
Dividend per share
N/A
Year To Date Return
-13.89%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Vectus Biosystems Ltd (ASX: VBS)
Latest News
Healthcare Shares
Why is this ASX biotech share leaping 14% today?
VBS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Vectus Biosystems Ltd
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis.Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
VBS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Feb 2026 | $0.16 | $0.00 | 0.00% | 6,451 | $0.16 | $0.16 | $0.16 |
| 13 Feb 2026 | $0.16 | $0.01 | 6.90% | 17,881 | $0.15 | $0.16 | $0.15 |
| 11 Feb 2026 | $0.15 | $-0.01 | -6.45% | 82,371 | $0.14 | $0.15 | $0.14 |
| 09 Feb 2026 | $0.16 | $0.01 | 7.14% | 120,434 | $0.15 | $0.16 | $0.15 |
| 06 Feb 2026 | $0.14 | $0.01 | 7.41% | 107,500 | $0.13 | $0.14 | $0.13 |
| 05 Feb 2026 | $0.14 | $0.02 | 17.39% | 11,449 | $0.12 | $0.14 | $0.12 |
| 04 Feb 2026 | $0.12 | $0.00 | 0.00% | 112,074 | $0.12 | $0.12 | $0.12 |
| 03 Feb 2026 | $0.12 | $-0.01 | -8.00% | 10,465 | $0.12 | $0.12 | $0.12 |
| 02 Feb 2026 | $0.13 | $-0.02 | -14.29% | 38,359 | $0.13 | $0.13 | $0.13 |
| 30 Jan 2026 | $0.14 | $0.00 | 0.00% | 30,653 | $0.14 | $0.14 | $0.14 |
| 29 Jan 2026 | $0.14 | $0.01 | 7.69% | 20,000 | $0.14 | $0.14 | $0.14 |
| 27 Jan 2026 | $0.13 | $0.00 | 0.00% | 33,270 | $0.13 | $0.13 | $0.13 |
| 23 Jan 2026 | $0.13 | $0.01 | 8.00% | 47,001 | $0.13 | $0.14 | $0.13 |
| 22 Jan 2026 | $0.13 | $-0.01 | -7.69% | 24,679 | $0.13 | $0.13 | $0.13 |
| 21 Jan 2026 | $0.13 | $0.00 | 0.00% | 121,691 | $0.14 | $0.14 | $0.13 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Maurie Stang | Non-Executive Deputy ChairmanNon-Executive Director | Dec 2005 |
Mr Stang has four decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His business development and marketing skills have resulted in the commercialization of intellectual property across global markets. He has been the Executive Chairman of unlisted company Lumitron Technologies since 2016. He is also a member of Corporate Governance Committee.
|
| Dr Ronald Cecil Shnier | Non-Executive DirectorNon-Executive Chairman | Sep 2015 |
Dr Shnier was a consultant specialist at RPAH between 1990 and 1993. He started one of Australia's first Private MRI practices in 1991 before becoming General Manager of Mayne's Diagnostic Imaging in 2007 and was its National Director for many years. He has served on several international MRI advisory boards. He has an involvement in clinical research and has lectured both in Australia and overseas. He is currently the Chief Medical Officer of I-MED Radiology network and an executive director on the board. He is also currently a non-executive director on the Board of Lumitron Technologies. He is the chairman of Disclosure Committee and member of Risk Management Committee.
|
| Ms Linda Ann Walters | Non-Executive Director | Dec 2024 |
Ms Walters has operational, commercial and technical background across several life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. She has made contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization program. She is also a member of Corporate Governance Committee.
|
| Mr Robert John Waring | Company Secretary |
-
|
|
| Robert John Waring | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Kefford Holdings Pty Ltd <The Kefford Family A/C> | 5,187,623 | 9.73% |
| Ajjika Technology Pty Limited <The Ajjika A/C> | 3,200,000 | 6.00% |
| Bernard Stang | 2,764,500 | 5.18% |
| J P Morgan Nominees Australia Pty Limited | 2,705,329 | 5.07% |
| Energy Trading Systems Pty Ltd <The MPF A/C> | 2,562,500 | 4.80% |
| Maurie Stang | 2,285,952 | 4.29% |
| Towns Corporation Pty Ltd <Pae Family A/C> | 1,984,976 | 3.72% |
| Gleneagle Securities Nominees Pty Limited | 1,611,596 | 3.02% |
| Bennelong Resources Pty Ltd <John Egan Super Fund A/C> | 1,500,000 | 2.81% |
| Spinite Pty Ltd | 1,435,773 | 2.69% |
| Citicorp Nominees Pty Limited | 1,168,124 | 2.19% |
| Grizzly Holdings Pty Limited | 999,680 | 1.87% |
| Gleneagle Securities (Aust) Pty Ltd | 938,675 | 1.76% |
| Exit Out Pty Ltd <The Discretionary A/C> | 900,000 | 1.69% |
| Buttonwood Nominees Pty Ltd | 859,112 | 1.61% |
| Robert Richter + Anne Lyell Richter <Robert Richter S/F No2 A/C> | 825,291 | 1.55% |
| Esklaw Pty Ltd <Tom Forrester Family A/C> | 814,000 | 1.53% |
| T S Rai 2 Pty Ltd <Websta Super Fund A/C> | 800,000 | 1.50% |
| Paul Alexander Ehrlich + Lauren Stacey Ehrlich <PAE & LSE Super Fund A/C> | 730,000 | 1.37% |
| TDF Properties Pty Ltd <The TDF Property A/C> | 599,339 | 1.13% |
